The Medical Letter - 2020
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
January 27, 2020 (Issue 1590)
- Drugs for ADHD
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into... - In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)....
January 13, 2020 (Issue 1589)
- Antiviral Drugs for Influenza
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase... - Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for... - Corticosteroids in Community-Acquired Pneumonia
Recently updated guidelines from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) address the use of corticosteroids as an adjunct to antimicrobials... - Expanded Table: Antiviral Drugs for Influenza (online only)
View the Expanded Table: Antiviral Drugs for Influenza
